Rahul Srinivasan, Chief Financial Officer, said “This record-breaking quarter stands as a testament to the passion and commitment of our entire team at Grifols (GRFS) towards our mission of improving patients’ lives globally and supporting our donors. We remain firmly focused on our ongoing priorities of deleveraging and free cash flow generation.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GRFS:
- Brookfield awaiting information for potential Grifols bid, Bloomberg says
- Brookfield still pursuing Grifols deal, Bloomberg reports
- Grifols SA (GRFS) Q3 Earnings Cheat Sheet
- Grifols price target lowered to EUR 15.50 from EUR 15.60 at Berenberg
- Grifols receives FDA approval to treat surgical bleeding with FS solution